The Wistar Institute

2017–2022 · research · R01

Multivalent DNA vaccine-mediated protection against Tuberculosis

David B. Weiner · The Wistar Institute · funded by National Institutes of Health

$675.6kTuberculosis Research and Epidemiology

2017–2018 · fellowship · F32

Targeting hyaluronan in the tumor microenvironment to improve DNA vaccine immunotherapy

Elizabeth Kennedy Duperret · The Wistar Institute · funded by National Institutes of Health

$37kProteoglycans and glycosaminoglycans research

2017–2022 · research · R01

Targeting TERT in Melanoma

Jessie Villanueva · The Wistar Institute · funded by National Institutes of Health

$439.2k

2017–2024 · research · R35

Tumor Plasticity

Dario C Altieri · The Wistar Institute · funded by National Institutes of Health

$900k

2017–2022 · research · R01

Effect of the aged microenvironment on tumor dormancy

Ashani T Weeraratna · The Wistar Institute · funded by National Institutes of Health

$434.6kCancer Cells and Metastasis

2017–2024 · research · R01

Multivalent DNA vaccine-mediated protection against Tuberculosis

David B. Weiner · The Wistar Institute · funded by National Institutes of Health

$865.3kTuberculosis Research and Epidemiology

2017–2022 · cooperative agreement · U54

Rational approaches to melanoma therapy

Michael Davies · The Wistar Institute · funded by National Institutes of Health

$36k

2017–2027 · research · R50

Advancing Cancer Research through Comprehensive Proteomics and Metabolomics Analyses

Hsin-Yao Tang · The Wistar Institute · funded by National Institutes of Health

$237.1k

2017–2018 · research · R21

Role of Host Glycosylation in the Galectin-9-Mediated Reversal of HIV Latency

Mohamed Abdel Mohsen · The Wistar Institute · funded by National Institutes of Health

$282.9kGalectins and Cancer Biology

2017–2022 · research · R01

Targeting TERT in Melanoma

Jessie Villanueva · The Wistar Institute · funded by National Institutes of Health

$64.1k

2017–2022 · cooperative agreement · U54

Rational approaches to melanoma therapy

Michael Davies · The Wistar Institute · funded by National Institutes of Health

$1.4M

2017–2024 · research · R35

Tumor Plasticity

Dario C Altieri · The Wistar Institute · funded by National Institutes of Health

$1.1M

2017–2022 · research · R01

Negative regulation of myeloid-derived suppressive cells in cancer

Serge Y Fuchs · The Wistar Institute · funded by National Institutes of Health

$457.1kImmune cells in cancer

2017–2022 · research · R50

Advancing Cancer Research through Comprehensive Proteomics and Metabolomics Analyses

Hsin-Yao Tang · The Wistar Institute · funded by National Institutes of Health

$188.5k

2017–2022 · research · R01

Negative regulation of myeloid-derived suppressive cells in cancer

Serge Y Fuchs · The Wistar Institute · funded by National Institutes of Health

$547.5kImmune cells in cancer

2017–2020 · grant · BCRP

Twist Maintains Stemness in Latent Breast Cancer Metastases Through a Novel Non-DNA-Binding Function Targetable with Small Molecules

Frank Rauscher, Iii · The Wistar Institute · funded by Congressionally Directed Medical Research Programs

$473.8k

2017–2027 · research · R50

Advancing Cancer Research through Comprehensive Proteomics and Metabolomics Analyses

Hsin-Yao Tang · The Wistar Institute · funded by National Institutes of Health

$237.1k

2017–2028 · cooperative agreement · U54

Rational Approaches to Melanoma Therapy

Michael Davies · The Wistar Institute · funded by National Institutes of Health

$1.3M

2017–2028 · cooperative agreement · U54

Functional precision approaches to overcome intrinsic and acquired drug resistance in melanoma

Jessie Villanueva · The Wistar Institute · funded by National Institutes of Health

2017–2023 · cooperative agreement · U54

Administrative Core

Meenhard F Herlyn · The Wistar Institute · funded by National Institutes of Health

2017–2023 · cooperative agreement · U54

Research Project 2 - Targeting Melanoma Tumor Survival and Apoptotic Machinery

Michael Davies · The Wistar Institute · funded by National Institutes of Health

2017–2023 · cooperative agreement · U54

Bioinformatics Core

Andrew V Kossenkov · The Wistar Institute · funded by National Institutes of Health

2017–2023 · cooperative agreement · U19

Administration

David B. Weiner · The Wistar Institute · funded by National Institutes of Health

2017–2023 · cooperative agreement · U54

Bioinformatics Core

Andrew V Kossenkov · The Wistar Institute · funded by National Institutes of Health

2017–2023 · cooperative agreement · U54

Research Project 1 - Targeting the MAPK and PI3K pathways in melanoma PDX

Meenhard F Herlyn · The Wistar Institute · funded by National Institutes of Health

2017–2023 · cooperative agreement · U54

Administrative Core

Meenhard F Herlyn · The Wistar Institute · funded by National Institutes of Health

2017–2023 · cooperative agreement · U54

Administrative Core

Meenhard F Herlyn · The Wistar Institute · funded by National Institutes of Health

2017–2028 · cooperative agreement · U54

PDX Core

Meenhard F Herlyn · The Wistar Institute · funded by National Institutes of Health

2017–2028 · cooperative agreement · U54

Bioinformatics Core

Andrew V Kossenkov · The Wistar Institute · funded by National Institutes of Health

2017–2023 · cooperative agreement · U54

Administrative Core

Meenhard F Herlyn · The Wistar Institute · funded by National Institutes of Health

2017–2023 · cooperative agreement · U54

PDX Core

Meenhard F Herlyn · The Wistar Institute · funded by National Institutes of Health

2017–2028 · cooperative agreement · U54

Pilot-Trans Network Core

Meenhard F Herlyn · The Wistar Institute · funded by National Institutes of Health

2017–2023 · cooperative agreement · U54

Research Project 2 - Targeting Melanoma Tumor Survival and Apoptotic Machinery

Michael Davies · The Wistar Institute · funded by National Institutes of Health

2017–2023 · cooperative agreement · U54

Pilot Projects and Trans-Network Activities Core

Meenhard F Herlyn · The Wistar Institute · funded by National Institutes of Health

2017–2023 · cooperative agreement · U54

Pilot Projects and Trans-Network Activities Core

Meenhard F Herlyn · The Wistar Institute · funded by National Institutes of Health

2017–2023 · cooperative agreement · U54

PDX Core

Meenhard F Herlyn · The Wistar Institute · funded by National Institutes of Health

2017–2028 · cooperative agreement · U54

Administrative Core

Jessie Villanueva · The Wistar Institute · funded by National Institutes of Health

2017–2023 · cooperative agreement · U54

Research Project 1 - Targeting the MAPK and PI3K pathways in melanoma PDX

Meenhard F Herlyn · The Wistar Institute · funded by National Institutes of Health

2017–2028 · cooperative agreement · U54

Personalized targeting of anti-apoptosis pathways to overcome therapeutic resistance in melanoma

Michael Davies · The Wistar Institute · funded by National Institutes of Health

2016–2021 · cooperative agreement · U01

Integration of Biomarker Signatures from Peripheral Blood for Diagnosis, Prognosis, Remission and Recurrence of Lung Cancer

Qihong Huang · The Wistar Institute · funded by National Institutes of Health

$682.9kLung Cancer Diagnosis and Treatment